Acceleron  

Publications

A Phase 2 Randomized Study of Dalantercept Plus Axitinib Versus Placebo Plus Axitinib in Advanced Renal Cell Carcinoma: Results from the Part 1 Dose Escalation and Expansion Cohorts. American Society of Oncology Annual Meeting; May 30 – June 3, 2014
+ DOWNLOAD PDF